Sorrento Therapeutics, Inc. - Laporan Laba Rugi (TTM)

Sorrento Therapeutics, Inc.
US ˙ OTCPK ˙ US83587F2020
HINDI NA ACTIVE ANG SIMBONG ITO

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Sorrento Therapeutics, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
Revenue 42 40 47 51 51 53 57 55 60 63 61 64
Change (%) -3.68 16.34 9.68 0.61 3.06 7.81 -3.60 9.71 4.17 -3.40 5.87
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 115 121 145 176 194 220 242 239 262 255 234 222
Change (%) 5.51 19.48 21.55 10.31 13.21 10.24 -1.53 9.81 -2.86 -8.15 -5.21
% of Revenue 276.88 303.31 311.49 345.20 378.50 415.76 425.13 434.25 434.65 405.29 385.36 345.01
Gross Operating Profit -73 -81 -98 -125 -143 -167 -185 -184 -202 -192 -173 -157
Change (%) 10.70 21.02 27.16 14.27 16.85 11.01 -0.89 9.84 -4.97 -9.70 -9.10
% of Revenue -176.88 -203.31 -211.49 -245.20 -278.50 -315.76 -325.13 -334.25 -334.65 -305.29 -285.36 -245.01
SG&A 100 116 133 159 183 197 198 196 198 182 193 194
Change (%) 15.65 14.71 19.38 15.23 7.38 0.47 -0.96 0.85 -7.70 5.84 0.29
% of Revenue 241.98 290.55 286.49 311.82 357.13 372.10 346.79 356.26 327.50 290.17 317.91 301.14
R&D
Change (%)
% of Revenue
OpEx 219 242 282 339 382 421 444 439 464 441 431 420
Change (%) 10.07 16.88 20.24 12.48 10.26 5.57 -1.27 5.75 -4.88 -2.27 -2.68
% of Revenue 528.52 603.99 606.78 665.20 743.70 795.68 779.18 797.97 769.16 702.33 710.55 653.17
Operating Income -178 -202 -236 -288 -330 -368 -387 -384 -404 -379 -371 -356
Change (%) 13.28 16.99 22.32 14.58 11.38 5.25 -0.93 5.18 -6.23 -2.08 -4.08
% of Revenue -428.52 -503.99 -506.78 -565.20 -643.70 -695.68 -679.18 -697.97 -669.16 -602.33 -610.55 -553.17
Interest Expense -26 -20 -16 -9 -10 -10 -11 -11 -9 -9 -6 -7
Change (%) -21.70 -22.03 -39.95 3.57 4.59 8.64 2.68 -18.48 -7.78 -24.69 5.48
% of Revenue -62.01 -50.41 -33.79 -18.50 -19.04 -19.33 -19.47 -20.74 -15.41 -13.64 -10.64 -10.60
Net Income -290 -298 -231 -320 -355 -428 -472 -524 -494 -573 -672 -548
Change (%) 3.00 -22.68 38.51 11.19 20.52 10.11 11.06 -5.77 16.06 17.25 -18.41
% of Revenue -698.01 -746.41 -496.04 -626.43 -692.36 -809.63 -826.96 -952.65 -818.24 -911.60 -1,106.41 -852.65

Source: Capital IQ

Other Listings
US:SRNE
GB:0L85
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista